BACKGROUND Thoracic endovascular aortic repair (TEVAR) has been used in patients with uncomplicated type B acute
Given that a thrombosed false lumen predicts lower event rates with type B-AAD (7) and favorable false lumen remolding after TEVAR for type B aortic dissection (8) (9) (10) , TEVAR has also been used in patients with uncomplicated type B-AAD to reduce late morbidity and mortality (8, 11, 12) . Recently, several studies have compared early and late outcomes of TEVAR and BMT in patients with type B-AAD (8, (11) (12) (13) (14) (15) (16) . However, the findings of these studies of patients with uncomplicated type B-AAD have been inconsistent, likely due to different patient enrollment criteria (8, 11, 12, 15) and/or short follow-up duration (11, (14) (15) (16) .
For patients treated with BMT, mortality rates at 3, 5, and 6 years have previously been reported as 22.4% (17) , 27 .9% (18) , and 42% (5) Values are mean AE SD or n (%).
BMT ¼ best medical treatment; TEVAR ¼ thoracic endovascular aortic repair.
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A STATISTICAL ANALYSIS. Significant differences between groups were determined with the Fisher exact test for categorical variables and Student t tests for continuous variables. A Kaplan-Meier analysis was used to estimate the overall survival and freedom from aortic-related adverse events, and log-rank tests were used to discriminate between the Kaplan-Meier curves. All of the these statistical tests were 2-sided, and the significance level was <0.05. Statistical Values are mean AE SD or n (%).
A-AD ¼ type A aortic dissection; CTA ¼ computed tomography angiography; SINE ¼ stent graft-induced new entry; other abbreviations as in Table 1 . The aortic-related adverse event rate for patients with uncomplicated type B acute aortic dissection at 5 years was 28.2% in the TEVAR group and 37.8% in the BMT group. A logrank test showed significant difference between the 2 curves (p ¼ 0.025). BMT ¼ best medical treatment; TEVAR ¼ thoracic endovascular aortic repair.
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analyses were performed using SPSS version 13.0 (SPSS, Chicago, Illinois).
RESULTS BASELINE CHARACTERISTICS.
A total of 338 patients were enrolled in this study, with TEVAR procedures performed on 184 patients (TEVAR group).
The baseline characteristics, comorbidity profiles, extension of dissection, and patency of false lumen were evenly distributed between the TEVAR and BMT groups ( Table 1) . A B
(A) The mortality rate from all-cause death at year 5 was lower with TEVAR compared with BMT (10.8% vs. 14.3%). Log-rank tests showed significant difference between the 2 curves (p ¼ 0.010). (B) The mortality rates of both aortic-related and unknown death at 5 years was 9.2% in the TEVAR group and 12.1% in the BMT group. Log-rank tests showed a significant difference between the 2 curves (p ¼ 0.012). Abbreviations as in Figure 1 . Table 2) .
Late event rate was significantly higher in the BMT group compared with the TEVAR group (p ¼ 0.005) ( Table 2) . A total of 50 late deaths were reported, including 27 aortic-related late deaths, 24 of which were due to a ruptured false lumen in the descending In a retrospective study of 338 patients with uncomplicated type B acute aortic dissection (B-AAD), management strategies involving thoracic endovascular aortic repair (TEVAR) and best medical treatment (BMT) were compared. In the short term (<30 days), BMT produced fewer aortic-related events and deaths, but the difference was not significant. However, TEVAR proved significantly better than BMT in reducing the rates of both adverse events and mortality at 30 days and beyond. The early event rate in patients with uncomplicated type B-AAD who are treated with TEVAR was largely unknown. In our study, the early event rate in the TEVAR group was 10.3%, which was higher than that of the BMT group (4.5%), although the difference was not statistically significant. The early event rate in the BMT group was consistent with findings from previous studies (19, 20) . In previous studies, the early mortality rates in patients with type B aortic dissection treated with TEVAR range between 2.4% and 10.9% (8, 14) and, in patients treated with BMT, the range has been between 0% and 10.6% (5, 11, 21, 22) . In a different approach from previous studies, the ADSORB (Acute Dissection Stent Grafting or Best Medical Treatment) trial was the first randomized trial to compared BMT with TEVAR for patients with uncomplicated type B-AAD (13). In the ADSORB trial (16) , no deaths occurred in either the TEVAR or BMT group during the first 30 days. In our study, the early mortality rate was 0.5% with TEVAR and 2.6% with BMT. However, compared with other studies, 30-day mortality rates were lower in patients treated with TEVAR in both the ADSORB trial and our research. This discrepancy can be explained by the remarkable difference in pretreatment patient selection. The patients who were selected for TEVAR in the early reports presented with complicated type B aortic dissection or combined series including both acute and chronic type B aortic dissection. By contrast, the patients assigned to TEVAR in the ADSORB trial (16) and our study had only uncomplicated type B-AAD.
In the present study, the main causes of late events in patients treated with BMT were aortic enlargement Log Rank P=0.006
Aortic-related adverse events and all-cause death were composited and analyzed. The rate of both aortic-related adverse events and all-cause death at 5-year follow-up was 29.3% in the TEVAR group and 39.7% in the BMT group. A log-rank test showed significant difference between the 2 curves (p ¼ 0.006). Abbreviations as in Figure 1 .
CTA imaging in this study. Consistent with an earlier report (23) , SINE was a severe complication in the TEVAR group and was associated with substantial mortality The patients in the BMT group experienced more aortic-related adverse events than those treated with TEVAR (Figure 1) , and this result was partially consistent with our earlier report (11) .
Previous studies in patients with complicated and uncomplicated type B-AAD treated with TEVAR have reported 1-and 5-year overall survival rates of 83% and 79%, respectively (24) . In the longest follow-up to date for overall survival in patients with type B-AAD treated with BMT, the overall survival rates are 35% and 17% at 10 and 15 years, respectively (25) Aortic rupture is the primary cause of aortic-related death following TEVAR and comprises 50% to 100% of all causes of death (12, 29, 30) . The aortic-related deaths in our series were also mostly due to aortic rupture (24 of 27; 88.9%). There were an additional 3 deaths due to retrograde type A-AD that occurred during follow-up. We cannot exclude the possibility that the deaths of unknown etiology might also be due to aortic-related events, such as retrograde type A-AD or rupture. Therefore, both aortic-related and unknown deaths were composited and analyzed, and the patients in the BMT group had more deaths compared with the TEVAR group ( Figure 2B) . In the present study, both aortic-related adverse events and all-cause deaths were also combined and analyzed; the patients in the BMT group had significantly more events compared with the TEVAR group (Figure 3) . 
